Figure 2. Deep proteome and phosphoproteome analysis of atorvastatin-treated ESCC cells. (A) general workflow of the experimental strategy to illustrate the processes in proteome, and phosphoproteome profiles of KYSE150 cells after 24 h of atorvastatin treatment (1 μM). (B) Mass error distribution map and peptide length distribution map of identified peptides in proteomics. (C) Mass error distribution map and peptide length distribution map of identified peptides in phosphoproteomics. The quality control report conforms to standard.